Latest Headlines

  1. Labcorp To Offer First FDA-Cleared Blood Test To Rule out Alzheimer's-Related Amyloid Pathology In Primary Care Settings 10/23/2025

    Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will offer the Elecsys pTau181 test, the only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment for Alzheimer's disease and other causes of cognitive decline in the primary-care setting.

  2. Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement To Develop Droplet Digital™ PCR High Complexity Assays 10/22/2025

    Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic markers focused on oncology applications, utilizing Bio-Rad’s Droplet Digital™ PCR (ddPCR™) technology on Bio-Rad’s QX600 platform.

  3. Aiforia Signs A Local Agreement With Siemens Healthineers Finland 10/22/2025

    Aiforia Technologies, a leading Finnish provider of deep learning AI solutions for digital pathology, has entered into a local agreement with Siemens Healthineers Finland.

  4. OncoHost Receives New York State Laboratory Permit, Expanding Availability Of PROphetNSCLC® Precision Oncology Test 10/22/2025

    OncoHost, a technology company transforming the approach to precision medicine through plasma proteomics and AI, today announced that it has received a laboratory permit from the New York State Department of Health Wadsworth Center.

  5. Diasorin Signs A Supplier Agreement With Quest Diagnostics For The Innovative Molecular Multiplexing Platform, LIAISON PLEX 10/22/2025

    Diasorin today announced the signing of a supplier agreement with Quest Diagnostics a leading provider of diagnostic information services based in and serving the United States.

  6. Plus Therapeutics Updates On CNSide® Diagnostic Platform Launch 10/21/2025

    Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces continued operational execution and commercial progress in the launch of its wholly owned subsidiary, CNSide Diagnostic LLC’s, Cerebrospinal Fluid (CSF) Tumor Cell Enumeration laboratory developed test (LDT).

  7. Seek Labs Expands Global Disease Atlas With Mapping Of Hemorrhagic Fever Viruses Through BioSeeker 10/21/2025

    Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery programmable therapeutics, and point-of-care diagnostics, today announced an expansion of its Global Disease Atlas to include multiple hemorrhagic fever viruses.

  8. GeneDx Granted FDA Breakthrough Device Designation For Its ExomeDx And GenomeDx Testing 10/20/2025

    GeneDx a leader in delivering improved health outcomes through genomic insights, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its whole genome and exome tests associated with causes of life-threatening diseases or genetic disorders to aid in diagnosis of symptomatic patients.

  9. Samsung And GRAIL Announce Strategic Collaboration To Bring GRAIL's Galleri Multi-Cancer Early Detection Test To Asia 10/17/2025

    Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. today announced they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL’s Galleri multi-cancer early detection (MCED) test to key Asian markets.

  10. MVZ HPH Brings ctDNA Blood Test For Cancer Monitoring To Europe, Based On Haystack MRD® Technology From Quest Diagnostics® 10/17/2025

    MVZ HPH Institute for Pathology and Hematopathology GmbH, today announced the availability of HPH MRD, a new tumor-informed circulating-tumor DNA (ctDNA) blood test for detecting minimal residual disease (MRD) in patients diagnosed with solid tumor cancers.